Learn more

TARGETED GENETICS CORP

Overview
  • Total Patents
    125
About

TARGETED GENETICS CORP has a total of 125 patent applications. Its first patent ever was published in 1994. It filed its patents most often in Australia, Canada and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and organic fine chemistry are IBEX BIOSCIENCES LLC, GEMINI THERAPEUTICS INC and SHENZHEN GENO IMMUNE MEDICAL INST.

Patent filings in countries

World map showing TARGETED GENETICS CORPs patent filings in countries

Patent filings per year

Chart showing TARGETED GENETICS CORPs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Burstein Haim 22
#2 Stepan Anthony M 20
#3 Lynch Carmel M 17
#4 Feldhaus Andrew L 16
#5 Allen James M 15
#6 Takeya Ryan K 15
#7 Lupton Stephen D 14
#8 Wilkins Perry C 13
#9 Fung Victor P 13
#10 Reynolds Thomas C 13

Latest patents

Publication Filing date Title
AU2008207383A1 Enhancement of expression of a single-stranded heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
AU2007205720A1 Methods for generating high titer helper-free preparations of recombinant AAV vectors
AU2006344750A1 Methods for treating target joints in inflammatory arthritis using AAV vectors encoding a TNF antagonist
AU2006230419A1 Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
WO2006073496A2 Recombinant aav based vaccine methods
AU2005202946A1 Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
AU2004203863A1 Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU2004227358A1 Compounds and methods to enhance rAAV transduction
AU2003204921B2 Methods for generating high titer helper-free preparations of recombinant AAV vectors
AU2003203790B2 Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors
AU2002256398A2 Lipid-comprising drug delivery complexes and methods for their production
US6989264B2 Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU2646901A Methods for transducing cells in blood vessels using recombinant AAV vectors
US6924128B2 Packaging cell lines for generation of high titers of recombinant AAV vectors
US6596535B1 Metabolically activated recombinant viral vectors and methods for the preparation and use
EP1916258A2 Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
WO0073481A1 Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
EP1939300A1 Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6893865B1 Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6566118B1 Methods for generating high titer helper-free preparations of released recombinant AAV vectors